相关实验视频

Updated: Jun 1, 2025

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

毒素A导致的尿路感染 - 我们应该保护吗? 一个随机对照试验

Anastasiya Holubyeva¹, Kaythi Khin², Tess Gao²

¹Department of Urogynecology and Reconstructive Pelvic Surgery, Atlantic Health System, 435 South Street, Suite 370, Morristown, NJ, 07960, USA. a.holubyeva@gmail.com.

International urogynecology journal

|January 21, 2025

概括

抗生素预防不需要预防尿路感染 (UTI) 后,毒素A注射过活的膀 (OAB). 这项研究发现,接受抗生素和不接受抗生素的患者之间的尿路感染率没有显著差异.

科学领域:

泌尿器科泌尿器科泌尿器科泌尿器科
药理学药理学是指药理学的学科.
传染性疾病传染性疾病

背景情况:

毒素A注射是治疗过度活跃膀 (OAB) 的常见方法.
尿路感染 (UTI) 是侵入性手术后的潜在并发症.
在这种情况下,对于预防尿路感染的抗生素预防的必要性是有争议的.

研究的目的:

评估对抗生素预防的必要性,以预防尿路感染在OAB的Onabotulinum毒素A注射之前.
为了确定上述抗生素预防是否与其管理无差.

主要方法:

进行了一项多中心,非盲目的随机对照试验.
参与者被随机分配,接受口服抗生素或不接受治疗.
主要结局是手术后2周的尿路感染率;次要结局包括空洞后的残留物和6周的尿路感染率.

主要成果:

2周后的尿路感染率为9.2% (抗生素) 和10.9% (对照组),p=0.75.
6周后的尿路感染率为4.7% (抗生素) 和11.1% (对照组),p=0.21.
没有任何程序前的因素预测了2周后尿路感染的发展;尿留率为0.8%.

结论:

在2周和6周的组之间没有观察到尿路感染率的显著差异.
忽略抗生素预防可以考虑打击抗菌素耐药性.
这种方法可能是安全的OAB治疗与onabotulinum毒素A.这种方法可能是安全的.

关键词:

抗生素耐药性抗生素耐药性一种类毒素毒素A 一种类毒素过度活动的膀.尿路感染尿路感染

更多相关视频

Transurethral Induction of Mouse Urinary Tract Infection

Transurethral Induction of Mouse Urinary Tract Infection

Published on: August 5, 2010

Longitudinal Follow-Up of Urinary Tract Infections and Their Treatment in Mice using Bioluminescence Imaging

Longitudinal Follow-Up of Urinary Tract Infections and Their Treatment in Mice using Bioluminescence Imaging

Published on: June 14, 2021

相关概念视频

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...